Clinical trials: psoriasis
Psoriasis
UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis
Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis.
- Trial name
- NCT00638469
- Testing
- UVB-311nm, No treatment
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Graz
Rheumatoid Arthritis (RA, Ankylosing Spondylitis
Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk.
- Conditions
- Rheumatoid Arthritis (RA, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis (ReA)
- Trial name
- NCT07329556
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bursa City Hospital
Vitiligo Vulgaris, Psoriasis
PALLAS Laser for Skin Diseases
The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).
- Conditions
- Vitiligo Vulgaris, Psoriasis, Alopecia Areata, Atopic Dermatitis
- Trial name
- PALLAS-UV (NCT07250997)
- Testing
- UVB laser treatment
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- Szeged University
Psoriasis
Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients
The prevalence of cardiovascular risk in psoriasis has been reported in previous studies.Various studies have also shown that systemic treatments for psoriasis, including methotrexate, may significantly decrease this…
- Trial name
- NCT03904680
- Testing
- Methotrexate, Vitamin D
- Volunteers
- 30 people
- Sponsor
- Cairo University
Plaque Psoriasis
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
To compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis
- Trial name
- NCT05763082
- Testing
- roflumilast cream 0.3%, Zoryve
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Padagis LLC
Persistent Knee Joint Synovitis
Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis
To assess the therapeutic efficacy, of the clinical response of intraarticular (IA) etanercept (E) 12.5 mg or placebo (P: NaCl) injections into single knee arthritic joint of patients with refractory knee joint synovitis (KJS)…
- Trial name
- NCT00678782
- Testing
- etanercept
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- University of Padova
Rheumatoid Arthritis, Arthritis, Psoriatic
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database
The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan.The objective of this study is to…
- Conditions
- Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing Spondylitis
- Trial name
- NCT01081717
- Testing
- systemic non-biological treatments, anti-TNF biologics, golimumab
- Volunteers
- 1,064 people
- Sponsor
- Janssen Biotech, Inc.
Rheumatoid Arthritis, Spondyloarthritis
Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs
Background The risk for hospitalized infection (i.e. infection leading to hospitalization) in patients with inflammatory arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis
- Trial name
- NCT03496831
- Testing
- Biologic Agents
- Volunteers
- 7,500 people
- Sponsor
- Simon Krabbe
Psoriasis
Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients
case control study to compare level of interleukin 38 in patients with psoriasis and patients with metabolic syndrome with healthy control subjects
- Trial name
- NCT05076812
- Testing
- measure plasma level of interleukin 38 by ELISA kit
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sohag University
Plaque Psoriasis
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
- Trial name
- BDS1307 (NCT02070965)
- Testing
- DFD01 Spray, Comp01 Lotion
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Primus Pharmaceuticals
Plaque Psoriasis
A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis.
- Trial name
- AFFIRM-35 (NCT03591887)
- Testing
- ABY-035
- Where
- 18 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Affibody
Healthy, Psoriasis
Sleep, Circadian Rhythm & Skin Health
The purpose of this study is to explore the mechanisms behind how sleep quality may affect skin aging, skin integrity and skin disease.
- Conditions
- Healthy, Psoriasis, Eczema, Acne
- Trial name
- NCT02457000
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Palmoplantar Pustulosis
Immune Signature of Palmoplantar Pustulosis
This study is being done to learn more about a less common "type" of psoriasis, called palmoplantar pustulosis (PPP). The majority of the current treatments used for this type of psoriasis have only a moderate effect on PPP.
- Trial name
- PPP (NCT01780857)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Psoriatic Arthritis
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week…
- Trial name
- NCT06640257
- Testing
- SHR-1314 injection
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriasis
ProspectIve Cohort psoriASiS fOllow-up (PICASSO)
The main purpose of the PICASSO-project is to facilitate future psoriasis-research in dermatology. This register biobank will enable us to perform research in the field of metabolomics, mRNA-expression, cardiovascular impact and…
- Trial name
- PICASSO (NCT05122039)
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Psoriasis
Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis
Psoriasis is a chronic inflammatory cutaneous disease, affecting 3% of the French population. Among psoriatic patients, 80% feel pain or cutaneous discomfort related to their pathology.
- Trial name
- MicroPso (NCT02652065)
- Testing
- Acetylcholine iontophoresis, Sodium Nitroprussiate iontophoresis, ppi water iontophoresis
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Psoriasis, Synovitis
Comparison of the Frequency of Subclinic Synovitis in the Distal Interphalangeal Joints of the Hand in Psoriasis Patients
In this cross-sectional study, it was planned to compare the frequency of subclinical synovitis in the distal interphalangeal joints of the hands in psoriasis patients.
- Trial name
- NCT04750993
- Testing
- musculoskeletal ultrasonography
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ufuk University
Psoriasis
KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis
This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 in the treatment of patients with plaque-type psoriasis.
- Trial name
- NCT05522816
- Testing
- KX01 0.01% (0.1 mg/g), KX01 0.1% (1.0 mg/g), KX01 1% (10 mg/g) for 5 days
- Volunteers
- 28 people
- Sponsor
- PharmaEssentia
Plaque Psoriasis
A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara® in patients with Moderate-to-Severe Plaque Psoriasis.
- Trial name
- VESPUCCI (NCT04595409)
- Testing
- FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)
- Where
- 16 sites in Estonia, Georgia and 2 more
- Volunteers
- 392 people
- Sponsor
- Bioeq GmbH
Plaque Psoriasis
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by…
- Trial name
- STEPin (NCT03020199)
- Testing
- Secukinumab, nb-UVB
- Where
- 44 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 196 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.